Evidence map›Paper›PMID 41761607›Full record

ArticleAnimal models and experimental medicine2026

Characterizing a murine breast cancer mouse model reveals chromosomal abnormalities in structure and number of single-cell clones and the presence of rare cancer stem cell-like phenotypes.

Quy Van-Chanh Le, Zsuzsa S Kocsis, Sisi Liang, Yanrui Li, Briony L Gliddon, Sheree Bailey, Anh Thai-Quynh Nguyen, Tyron Turnbull, Stuart M Pitson, Zsolt Jurányi and 2 more

Abstract read
In one paragraph

Article in Animal models and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Quy Van-Chanh LeFuture Industries Institute, Adelaide University, Mawson Lakes, South Australia, Australia.
Zsuzsa S KocsisDepartment of Radiobiology and Diagnostic Onco-Cytogenetics, Centre of Radiotherapy, National Institute of Oncology, Budapest, Hungary.
Sisi LiangFuture Industries Institute, Adelaide University, Mawson Lakes, South Australia, Australia.
Yanrui LiFuture Industries Institute, Adelaide University, Mawson Lakes, South Australia, Australia.
Briony L GliddonCentre for Cancer Biology, Adelaide University and SA Pathology, Adelaide, South Australia, Australia.
Sheree BaileySchool of Pharmacy and Biomedical Science, College of Health, Adelaide University, Adelaide, South Australia, Australia.
Anh Thai-Quynh NguyenFuture Industries Institute, Adelaide University, Mawson Lakes, South Australia, Australia.
Tyron TurnbullSchool of Physics, Chemistry & Earth Science, College of Science, Adelaide University, Adelaide, South Australia, Australia.
Stuart M PitsonCentre for Cancer Biology, Adelaide University and SA Pathology, Adelaide, South Australia, Australia.
Zsolt JurányiDepartment of Radiobiology and Diagnostic Onco-Cytogenetics, Centre of Radiotherapy, National Institute of Oncology, Budapest, Hungary.
Hien LeDepartment of Radiation Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Ivan KempsonFuture Industries Institute, Adelaide University, Mawson Lakes, South Australia, Australia.ORCID 0000-0002-3886-9516

Funding

Hungarian Thematic Excellence Program TKP2021-EGA-44National Research, Development and Innovation Fund of the Ministry of Culture and Innovation under the National Laboratories Program (National Tumor Biology Laboratory 2022-2.1.1-NL-2022-00010Senior Research Fellowship from National Health and Medical Research Council of Australia 1156693Tour de Cure, Pioneering Grant RSP-253-18/19
6 · The paper itself

Abstract

Realistic models for cancer research representing disease progression that commensurately respond to therapeutics consistent with clinical observation are the holy grail for pre-clinical research and screening. Although such an ideal is elusive, well-characterized in vivo models facilitate our understanding of disease, progression, and therapeutic opportunities. Here, we characterize a commonly used syngeneic BALB/c mouse model of triple negative breast cancer (4T1) after establishing tumors in their flanks. Tumors developed at the subcutaneous injection site for all experimental mice and their volumes were monitored. We quantified a rare subset of breast cancer stem-like cells (CSCs), classified as CD44

Indexed as

Breast NeoplasmsChromosome AberrationsMammary Neoplasms, ExperimentalNeoplastic Stem CellsAnimalsCell Line, TumorDisease Models, AnimalFemaleMiceMice, Inbred BALB CPhenotypebreast cancercancer stem cellschromosome aberrationsmouse model

Identifiers

PMID41761607
PMCPMC13042899

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.